<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892020000400007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diagnóstico por citometría de flujo de paciente con leucemia linfoide crónica]]></article-title>
<article-title xml:lang="en"><![CDATA[Flow cytometry diagnosis of a patient with chronic lymphocytic leukemia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Triana Marrero]]></surname>
<given-names><![CDATA[Yenisey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marsán Suárez]]></surname>
<given-names><![CDATA[Vianed]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duarte Pérez]]></surname>
<given-names><![CDATA[Yaneisy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>36</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892020000400007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892020000400007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892020000400007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La citometría de flujo es una técnica de avanzada, objetiva y altamente sensible que permite el análisis y la cuantificación simultánea de múltiples parámetros celulares, muy utilizada en el estudio de la leucemia linfoide crónica, entidad caracterizada como un trastorno proliferativo maligno de linfocitos de aspecto maduro e incompetentes.  Objetivo: Describir la estrategia de diagnóstico del inmunofenotipaje por citometría de flujo de la leucemia linfoide crónica.  Métodos: Se analizó una muestra de médula ósea para la citometría de flujo de un paciente con sospecha clínica y morfológica de la leucemia linfoide crónica. El inmunofenotipaje celular se realizó con el empleo de anticuerpos monoclonales dirigidos contra los antígenos de diferenciación linfoides B y T. Se procedió a la lectura de la muestra en un citómetro GALLIOS, Beckman Coulter y los datos obtenidos se analizaron con el empleo del programa informático Kaluza.  Resultados: Los antígenos con expresión positiva fueron el CD19 (99,94 %), CD20 (81,56 %), CD5 (80,25 %), así como la coexpresión de CD5+/CD19+ (96,56 %), CD5+/CD20+ (80,56 %), CD19+/CD20+ (84,86 %), CD23 (62,65 %), CD49d (65,18 %), CD38 (52,17%). Se encontró monoclonalidad de la cadena ligera k en un 44,27 %. La expresión de los antígenos CD3, CD4, CD8y CD25 resultó negativa.  Conclusiones: La estrategia diagnóstica propuesta permitió identificar los antígenos más frecuentemente expresados en pacientes con leucemia linfoide crónica, así como la coexpresión de los mismos y la monoclonalidad de la cadena k, los cuales son marcadores celulares que permiten realizar el diagnóstico inmunofenotípico de la leucemia linfoide crónica, por citometría de flujo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Flow cytometry is an advanced, objective, highly sensitive technique for the simultaneous analysis and quantification of multiple cellular parameters. This technique is very common in the study of chronic lymphocytic leukemia, a condition defined as a malignant proliferative disorder of mature, incompetent lymphocytes.  Objective: Describe the diagnostic strategy for flow cytometry immunophenotyping of chronic lymphocytic leukemia.  Methods: Flow cytometry testing was performed of a bone marrow sample taken from a patient with clinical and morphological suspicion of chronic lymphocytic leukemia. Cell immunophenotyping was based on monoclonal antibodies targeted against lymphoid differentiation antigens B and T. The sample was read in a GALLIOS Beckman Coulter cytometer, and the data obtained were analyzed with the software Kaluza.  Results: Antigens with a positive expression were CD19 (99.94%), CD20 (81.56%), CD5 (80.25%), as well as the co-expression of CD5+/CD19+ (96.56%), CD5+/CD20+ (80.56%), CD19+/CD20+ (84.86%), CD23 (62.65%), CD49d (65.18%), CD38 (52.17%). Monoclonality of the k light chain was present in 44.27%. Expression of antigens CD3, CD4, CD8 and CD25 was found to be negative.  Conclusions: The diagnostic strategy proposed made it possible to identify the antigens most frequently expressed in patients with chronic lymphocytic leukemia, as well as their co-expression and the monoclonality of the k chain, all of which are cell markers allowing flow cytometry-based immunophenotypical diagnosis of chronic lymphocytic leukemia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[citometría de flujo]]></kwd>
<kwd lng="es"><![CDATA[inmunofenotipo]]></kwd>
<kwd lng="es"><![CDATA[leucemia linfoide crónica]]></kwd>
<kwd lng="es"><![CDATA[diagnóstico]]></kwd>
<kwd lng="en"><![CDATA[flow cytometry]]></kwd>
<kwd lng="en"><![CDATA[immunophenotype]]></kwd>
<kwd lng="en"><![CDATA[chronic lymphocytic leukemia]]></kwd>
<kwd lng="en"><![CDATA[diagnosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Triana Marrero]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Marsán Suárez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Ballester]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Domínguez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucemia linfoide crónica de células B revisión de sus aspectos etiopatogénicos, moleculares y pronósticos]]></article-title>
<source><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></source>
<year>2019</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eichhorst]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Robak]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Montserrat]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ghia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hillmen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hallek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic lymphocyticleukaemia ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2015</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>78-84</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Puerta]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Chacón]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucemia linfática crónica B Diagnóstico, pronóstico y tratamiento]]></article-title>
<source><![CDATA[Actual Med]]></source>
<year>2017</year>
<volume>100</volume>
<numero>800</numero>
<issue>800</issue>
<page-range>52-3</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdespino-Gómez]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucemia linfocítica crónica de linfocitos B un modelo personalizado de valoración clínica y molecular]]></article-title>
<source><![CDATA[Rev Hematol Mex]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>103-21</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrais]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Vescovi]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Valério]]></surname>
<given-names><![CDATA[IRM]]></given-names>
</name>
<name>
<surname><![CDATA[Lorand-Metzee]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[André Domingues]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Leão]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of chronic lymphocytic leukemia recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia]]></article-title>
<source><![CDATA[Rev Bras Hematol Hemoter]]></source>
<year>2016</year>
<volume>38</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>34657</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kipps]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Croce]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Packham]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wierda]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic lymphocytic leukaemia]]></article-title>
<source><![CDATA[Nat Rev Dis Primers]]></source>
<year>2017</year>
<volume>3</volume>
<page-range>160-96</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sall]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Touré]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Sall]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Ndour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sène]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics of chronic lymphocytic leukemia in Senegal]]></article-title>
<source><![CDATA[BMC Hematol]]></source>
<year>2016</year>
<volume>23</volume>
<page-range>16:10</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rai]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic lymphocytic leukemia (CLL)-Then and now]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2016</year>
<volume>91</volume>
<page-range>330-40</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pui]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Behm]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Crist]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2013</year>
<volume>82</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>343-62</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drenon]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fardel]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Fauchet]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Amiot]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Flow cytometry application for the diagnosis and the follow-up of hematological malignancies]]></article-title>
<source><![CDATA[Ann Biol Clin]]></source>
<year>2013</year>
<volume>60</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>663-72</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pagnucco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vanelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gervasi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multidimensional flow cytometry immuno phenotyping of hematologic malignancy]]></article-title>
<source><![CDATA[Ann N Y AcadSci]]></source>
<year>2013</year>
<volume>963</volume>
<page-range>313-21</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kussick]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kalnoski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Braziel]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prominent clonal B cell populations identified by flow cytometry in histologically reactive lymphoid proliferations]]></article-title>
<source><![CDATA[Am J ClinPathol]]></source>
<year>2004</year>
<volume>121</volume>
<page-range>464-72</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorigue]]></surname>
<given-names><![CDATA[Marc]]></given-names>
</name>
<name>
<surname><![CDATA[Juncà]]></surname>
<given-names><![CDATA[Jordi]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical chronic lymphocytic leukemia: Brief historical overview and current us age of anequivocal concept]]></article-title>
<source><![CDATA[Int J Lab Hematol]]></source>
<year>2019</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hallek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cheson]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Catovsky]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the diagnosis and treatment of chronic lymphocyticleukemia a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>111</volume>
<page-range>5446-56</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ivancevic]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Kurtovic]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Knezevic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Role of Immunophenotyping in Differential Diagnosis of Chronic Lymphocytic Leukemia]]></article-title>
<source><![CDATA[Srp Arh Celok Lek]]></source>
<year>2014</year>
<volume>142</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>197-203</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shahni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Siddiqui]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mukry]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of aberrant antigens in hematological malignancies A single center experience]]></article-title>
<source><![CDATA[Pak J Med Sci]]></source>
<year>2018</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>457-62</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nieto]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Teodosio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Henriques]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor ow cytometry approach]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2009</year>
<volume>114</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schroers]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Baraniskin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Heute]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kuhnhenn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alekseyev]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schmiegel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection of free immunoglobulin light chains in cerebro spinal fluids of patients with central nervous system lymphomas]]></article-title>
<source><![CDATA[Eur J Haematol]]></source>
<year>2010</year>
<volume>85</volume>
<page-range>236-42</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eichhorst]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Appendix 6 chronic lymphocytic leukaemia]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2016</year>
<volume>27</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>143-4</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<collab>International CLL-IPI working group</collab>
<article-title xml:lang=""><![CDATA[An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2016</year>
<volume>17</volume>
<page-range>779-90</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haq]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Uddin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Ghaffar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic markers in Chronic Lymphocytic Leukaemia. A flow cytometric analysis]]></article-title>
<source><![CDATA[Pak J Med Sci]]></source>
<year>2020</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>338-43</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eichhorst]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hallek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostication of chronic lymphocytic leukemia in the era of new agents]]></article-title>
<source><![CDATA[Hematology Am Soc Hematol Educ Program]]></source>
<year>2016</year>
<numero>1</numero>
<issue>1</issue>
<page-range>149-55</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Popova]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Blazheva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lukanov]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Naneva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tzvetkov]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Study of the immunological markers CD49d and CD38 in early-stage B-CLL patients]]></article-title>
<source><![CDATA[J IMAB]]></source>
<year>2018</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1883-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
